First Patients Reach 12-Month Endpoint in Pivotal Trial for Envoy Medical's Fully Implanted Cochlear Implant
COCH sits 90% above its 52-week low of $0.363 on light trading volume (0.2× avg).
Summary
Envoy Medical announced that the first three patients in its pivotal clinical trial for the fully implanted Acclaim cochlear implant have successfully completed their 12-month endpoint visit. This is a critical milestone as the primary endpoints for the trial are tied to 12-month data, and its achievement keeps the company on schedule for its Premarket Approval (PMA) submission to the FDA. This positive development provides a much-needed boost for the micro-cap company, which has recently disclosed a going concern warning, a highly dilutive offering, a Nasdaq delisting threat, and an auditor change. Successful completion of the trial and subsequent FDA approval are crucial for the company's long-term viability and commercialization efforts.
At the time of this announcement, COCH was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.1M. The 52-week trading range was $0.36 to $1.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.